FINWIRES · TerminalLIVE
FINWIRES

HKG:3696

17 stories mentioning HKG:3696Updated 8d ago

Every FINWIRES story that references HKG:3696, newest first.

Asia

Insilico Medicine's Pleural Mesothelioma Drug Receives US FDA Fast Track Designation; Shares Down 4%

Insilico Medicine (HKG:3696) said ISM6331 received fast-track designation from the U.S. Food and Drug Administration for the treatment of adult patients with unresectable malignant pleural mesothelioma, according to a Wednesday filing with the Hong Kong Stock Exchange.The company said the designation covers adult patients with unresectable malignant pleural mesothelioma.Shares of the biopharmaceutical company were down 4% in recent trade.

HKG:3696
Asia

Hong Kong Stocks Extend Gains Despite China's GDP Miss; Insilico Medicine Climbs

Hong Kong stocks held their momentum Wednesday as stronger-than-expected Chinese industrial output and retail sales data offset concerns over the country's weakest quarterly economic growth in more than three years.The Hang Seng Index rose 1.4%, or 340.37 points, to close at 24,681.10, while the Hang Seng China Enterprises Index gained 1%, or 81.30 points, to finish at 8,184.38.China's economy expanded 4.3% year over year in the second quarter, slowing from 5% in the previous quarter and marking its weakest pace of growth since the fourth quarter of 2022.However, June industrial output rose 5.3% from a year earlier, and retail sales increased 1%, with both figures exceeding analysts' expectations, suggesting resilience in economic activity.In corporate news, Insilico Medicine (HKG:3696) advanced over 10% after entering a strategic alliance with Bora Pharmaceuticals (TPE:6472) to collaborate on AI-driven drug discovery and development.

Hang SengHKG:3696
Asia

Insilico Medicine, Bora Pharmaceuticals Form AI Drug Discovery Alliance

Insilico Medicine (HKG:3696) said it entered into a strategic alliance with Bora Pharmaceuticals (TPE:6472) to collaborate on AI-driven drug discovery and development under a framework that could be valued at over $2.5 billion if fully implemented.The proposed collaboration, subject to the execution of definitive agreements, will combine Insilico's Pharma.AI platform for target discovery, generative chemistry and molecule optimization with Bora's drug development, manufacturing, quality and commercialization capabilities.The alliance aims to integrate AI-enabled drug discovery with development and manufacturing to accelerate the delivery of medicines for patients with unmet medical needs, according to a Wednesday news release.

HKG:3696TPE:6472
Asia

InSilico Medicine, CMS Expand Drug Development Partnership

InSilico Medicine (HKG:3696) expanded its collaboration with China Medical System (HKG:0867, SGX:8A8) to jointly develop innovative drugs for central nervous system diseases, according to a Monday filing with the Hong Kong bourse.Under the agreement, InSilico will combine its artificial intelligence drug discovery platform with CMS' research and development capabilities and therapeutic expertise to advance the programs.InSilico said it is eligible to receive milestone payments of up to 1.20 billion yuan, plus royalties based on net sales under the collaboration.

HKG:0867HKG:3696SGX:8A8
Asia

Insilico Medicine Forecasts Swing to Profit in H1; Shares Up 7%

Insilico Medicine (HKG:3696) said it expects net profit of $33.5 million to $39.5 million for the first half of 2026, a turnaround from the $19.2 million net loss recorded a year earlier, according to a Hong Kong bourse filing on Thursday.The firm attributed the turnaround to an expected 273% to 287% rise in revenue, to $102.5 million to $106.5 million, up from $27.5 million in the prior-year period.Shares of the company were up nearly 7% in recent morning trade.

HKG:3696
Asia

Insilico Medicine Strikes Drug Discovery Deal With Japan's Takeda Pharmaceutical

Insilico Medicine (HKG:3696) struck a drug discovery deal with Japan's Takeda Pharmaceutical (TYO:4502) that could net the company up to $600 million.In a Hong Kong bourse filing Thursday, Insilico Medicine said it will use its artificial intelligence-powered Pharma.AI platform to advance drug candidates across multiple therapeutic areas for Takeda.Insilico said the deal is valued at $600 million after accounting for the $60 million project initiation fee plus milestone payments. The company will also receive royalties on sales of commercialized drugs.

HKG:3696TYO:4502
Asia

Hong Kong Stocks Decline on Renewed U.S.-China Friction; Shenzhen HQVT Technology Shines on Debut

Hong Kong stocks fell on Monday as investors reacted to unchanged Chinese lending rates and renewed U.S.-China tensions after Beijing imposed export controls on several American entities.The Hang Seng Index fell 0.7%, or 156.29 points, to close at 23,768.52, while the Hang Seng China Enterprises Index dropped 0.8%, or 61.30 points, to finish at 7,914.74.The People's Bank of China kept the one-year loan prime rate, the benchmark for most corporate and household loans, at 3.00%, while the five-year rate, a reference for mortgage lending, remained at 3.50%.Meanwhile, China's Commerce Ministry added 10 U.S. entities to its export control list, immediately banning exports of dual-use items to those companies. The ministry said the measures were taken to safeguard national security and interests, describing them as a response to what it called the U.S. government's "malicious practices."The move followed Washington's recent decision to add several Chinese companies to a military-related entity list.In corporate news, Shenzhen HQVT Technology (HKG:1392) made its Hong Kong debut, closing nearly 271% higher at HK$26.70, compared with its offer price of HK$7.20.Insilico Medicine (HKG:3696) closed over 4% higher after entering a neuroimmune drug discovery collaboration with SK Biopharmaceuticals (KRX:326030), with the deal carrying a potential value of more than $2.5 billion.

Hang SengHKG:1392HKG:3696
Asia

Insilico Medicine, SK Biopharmaceuticals Strike $2.5 Billion AI Drug Discovery Pact

Insilico Medicine (HKG:3696) and SK Biopharmaceuticals (KRX:326030) have signed a drug discovery collaboration deal focused on neuroimmune disorders of the central nervous system, with a total potential value exceeding $2.5 billion, according to a Monday Hong Kong bourse filing.Under the agreement, Insilico will use its artificial intelligence-powered Pharma.AI platform and drug discovery capabilities to identify and optimize drug candidates. Whereas, SK Biopharmaceuticals will lead late-stage development and commercialization, the filing said.Insilico is eligible to receive up to $18 million in upfront and near-term milestone payments. The total potential value of the deal exceeds $2.5 billion, including development, regulatory, and commercial milestones, as well as single-digit royalties on future product sales.The collaboration focuses on neuroimmune diseases and expands Insilico's use of AI-driven drug discovery technologies in central nervous system disorders.

HKG:3696KRX:326030
Asia

InSilico Medicine Completes First Human Dosing of Parkinson's Disease Drug in Phase 1 Trial

InSilico Medicine Cayman (HKG:3696) completed first-in-human dosing in a phase 1 clinical trial of ISM8969, according to a Wednesday Hong Kong bourse filing.The oral NLRP3 inhibitor is being developed to treat chronic neuroinflammation and central nervous system disorders, including Parkinson's disease.The milestone marks the first clinical achievement under the company's co-development collaboration with Hygtia Therapeutics.

HKG:3696
Asia

Insilico Medicine to Join FTSE Global Equity Index Series

Insilico Medicine (HKG:3696) will be added to the FTSE Global Equity Index Series following FTSE Russell's quarterly review, according to a Monday Hong Kong bourse filing.The artificial intelligence drug discovery company will join the FTSE Global Small Cap Index, FTSE Global All Cap Index, and FTSE Global Total Cap Index, with the changes taking effect on June 22.

HKG:3696
Asia

InSilico Medicine Says No Decision Made on Abu Dhabi Secondary Listing

InSilico Medicine (HKG:3696) said it has not made any concrete decision on a secondary listing at this stage and will make further announcements if there are any material developments, according to a Wednesday Hong Kong bourse filing.Bloomberg reported earlier, citing people familiar with the matter, that the AI-driven drug discovery company was considering a secondary listing in Abu Dhabi, potentially becoming the first company from outside the Gulf to list shares on a regional exchange.The report said InSilico Medicine had held preliminary discussions about a listing on the Abu Dhabi Securities Exchange as early as this year.

HKG:3696
Asia

Market Chatter: InSilico Medicine Considering Secondary Listing in Abu Dhabi

InSilico Medicine (HKG:3696) is considering listing in Abu Dhabi less than a year after going public in Hong Kong, Bloomberg News reported Tuesday.The Boston-based biotechnology firm has held preliminary discussions to list shares on the Abu Dhabi Securities Exchange as early as this year, the report said, citing people familiar with the matter.InSilico Medicine was listed in Hong Kong in December 2025, raising HK$2.28 billion from its IPO. The Tencent Holdings-backed (HKG:0700) drug discovery company had a stellar trading debut with shares closing 25% higher than their IPO price of HK$24.05 in their first day of trading.Insilico has yet to respond to' request for comment at press time.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

HKG:0700HKG:3696
Asia

InSilico Medicine to Join Hang Seng Biotech Index as Constituent Stock

InSilico Medicine (HKG:3696) will be included as a constituent stock of the Hang Seng Biotech Index effective the close of market on June 5, according to a Tuesday Hong Kong bourse filing.The AI-driven drug discovery firm believes the inclusion reflects the capital market's recognition of its long-term growth potential.

HKG:3696
Asia

InSilico Medicine Invests $105 Million in Wealth Management Products

InSilico Medicine (HKG:3696) invested $105 million in wealth management products offered by CMB International and JPMorgan, according to a Hong Kong bourse filing Thursday.The AI-driven drug discovery firm invested $50 million in a money market fund managed by CMB International Asset Management with an expected 3.99% annualized rate of return; $50 million in a variable net asset value money market fund by JPMorgan Asset Management with an expected 3.85% annualized rate of return; and a further $5 million in a dual-currency deposit issued by JPMorgan Chase Bank with an expected 4.68% rate of return.The subscriptions were made with the view of "enhancing returns on surplus cash," the firm said.

HKG:3696
Asia

Insilico Medicine Wins China IND Nod for IPF Inhalation Therapy

InSilico Medicine (HKG:3696) said its investigational new drug application for an inhaled formulation of Rentosertib has been approved by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.The company said the drug is intended for the treatment of idiopathic pulmonary fibrosis.The approval supports a Phase 1 clinical study to evaluate safety, tolerability, and pharmacokinetics, the filing said.

HKG:3696
Asia

Insilico Medicine Nominates AI-Developed Brain Cancer Drug Candidate

Insilico Medicine (HKG:3696) has nominated a new preclinical drug candidate for glioblastoma using its artificial intelligence platform, according to a Friday Hong Kong bourse filing.The candidate, ISM0387, was developed by the company's United Arab Emirates team using its Pharma.AI system and progressed from design to optimization in under 12 months.Insilico said the drug showed improved activity, selectivity, and brain penetration in early studies, with potential as a treatment for brain cancer.

HKG:3696
Asia

InSilico Medicine Grants 3.7 Million RSUs Under Incentive Scheme

InSilico Medicine (HKG:3696) granted a little over 3.7 million restricted share units (RSUs) to certain participants under a post-IPO RSU scheme, according to a Tuesday Hong Kong bourse filing.The granting of the RSUs is subject to the fulfillment of the relevant performance targets, the AI-driven drug discovery and development company said.The firm now has around 24.2 million shares available for future grants under its RSU and share option incentive plans, of which 2.8 million shares will be available for future grant to service providers within the scheme mandate limit.

HKG:3696

Track with the FINWIRES app suite